GALT (Galectin Therapeutics) Momentum Rank : 1 (As of Mar. 05, 2025)

View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Momentum Rank?

Galectin Therapeutics has the Momentum Rank of 1.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Galectin Therapeutics's Momentum Rank

For the Biotechnology subindustry, Galectin Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galectin Therapeutics's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Momentum Rank falls into.

Galectin Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

PHPN:Germany

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Executives

Harold H. Shlevin	director, officer: Chief Executive Officer	C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Zordani Richard A. Jr.	director	467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
Kary Eldred	director	2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman	director	712 LAKEWAY DRIVE, KELLER TX 76248
Joel Lewis	director	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Jack W Callicutt	officer: Chief Financial Officer	75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
James C Czirr	director	4908 SOUTH ASHTON COURT, SPOKANE WA 99223
10x Fund, L.p.	10 percent owner	1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz	director	235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio	director	5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein	director, 10 percent owner	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes	officer: Chief Medical Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Peter G Traber	director, officer: President and CEO	430 THAMER LANE, HOUSTON TX 77025